Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice
Overview
Authors
Affiliations
Human immunodeficiency virus type one (HIV-1) tissue compartments are established soon after viral infection. However, the timing in which virus gains a permanent foothold in tissue and the cellular factors that control early viral-immune events are incompletely understood. These are critical events in studies of HIV-1 pathogenesis and in the development of viral reservoirs after antiretroviral therapy. Moreover, factors affecting the permanence of viral-tissue interactions underlie barriers designed to eliminate HIV-1 infection. To this end we investigated the temporal and spatial viral and host factors during HIV-1 seeding of tissue compartments. Two humanized NOD.Cg-Prkdc IL2rg/SzJ mouse models were employed. In the first, immune deficient mice were reconstituted with human CD34+ cord blood hematopoietic stem cells (HSC) (hu-HSC) and in the second mice were transplanted with adult mature human peripheral lymphocytes (hu-PBL). Both, in measure, reflect relationships between immune activation and viral infection as seen in an infected human host. Following humanization both mice models were infected with HIV-1 at 10 50% tissue culture infective doses. Viral nucleic acids and protein and immune cell profiles were assayed in brain, lung, spleen, liver, kidney, lymph nodes, bone marrow, and gut from 3 to 42 days. Peripheral CD4+ T cell loss began at 3 days together with detection of HIV-1 RNA in both mouse models after initiation of HIV-1 infection. HIV-1 was observed in all tested tissues at days 3 and 14 in hu- PBL and HSC mice, respectively. Immune impairment was most prominent in hu-PBL mice. T cell maturation and inflammation factors were linked directly to viral tissue seeding in both mouse models. We conclude that early viral tissue compartmentalization provides a roadmap for investigations into HIV-1 elimination.
Interventions during Early Infection: Opening a Window for an HIV Cure?.
Hiner C, Mueller A, Su H, Goldstein H Viruses. 2024; 16(10).
PMID: 39459922 PMC: 11512236. DOI: 10.3390/v16101588.
Generation of Anti-HIV CAR-T Cells for Preclinical Research.
Su H, Anthony-Gonda K, Orentas R, Dropulic B, Goldstein H Methods Mol Biol. 2024; 2807:287-298.
PMID: 38743236 DOI: 10.1007/978-1-0716-3862-0_20.
Accelerated Neuroimmune Dysfunction in Aged HIV-1-Infected Humanized Mice.
Zhang C, Su H, Waight E, Poluektova L, Gorantla S, Gendelman H Pharmaceuticals (Basel). 2024; 17(2).
PMID: 38399364 PMC: 10892358. DOI: 10.3390/ph17020149.
The development and improvement of immunodeficient mice and humanized immune system mouse models.
Chen J, Liao S, Xiao Z, Pan Q, Wang X, Shen K Front Immunol. 2022; 13:1007579.
PMID: 36341323 PMC: 9626807. DOI: 10.3389/fimmu.2022.1007579.
Lepard M, Yang J, Afkhami S, Nazli A, Zganiacz A, Tang S Viruses. 2022; 14(9).
PMID: 36146734 PMC: 9500899. DOI: 10.3390/v14091927.